v3.26.1
Related Party Transactions (Tables)
6 Months Ended
Jun. 30, 2026
Related Party Transactions [Abstract]  
Effects of reinsurance
Information regarding the significant effects of affiliated reinsurance on the interim condensed consolidated statements of operations and comprehensive income (loss) was as follows:
Three Months
Ended
June 30,
Six Months
Ended
June 30,
2026202520262025
(In millions)
Premiums
Reinsurance assumed
$$(1)$$
Reinsurance ceded
(112)(108)(223)(218)
Net premiums
$(110)$(109)$(219)$(215)
Universal life and investment-type product policy fees
Reinsurance assumed
$12 $$25 $15 
Reinsurance ceded
— — (1)
Net universal life and investment-type product policy fees
$12 $$26 $14 
Other revenues
Reinsurance assumed
$26 $30 $52 $55 
Reinsurance ceded
112 114 224 226 
Net other revenues
$138 $144 $276 $281 
Policyholder benefits and claims
Reinsurance assumed
$$$13 $18 
Reinsurance ceded
(89)(86)(180)(175)
Net policyholder benefits and claims
$(84)$(78)$(167)$(157)
Policyholder liability remeasurement (gains) losses
Reinsurance assumed$$(2)$$(3)
Reinsurance ceded— (3)— 
Net policyholder liability remeasurement (gains) losses$$(1)$(1)$(3)
Interest credited to PABs
Reinsurance assumed
$81 $84 $163 $170 
Reinsurance ceded
(3)(3)(5)(5)
Net interest credited to PABs
$78 $81 $158 $165 
Other expenses
Reinsurance assumed
$25 $12 $170 $23 
Reinsurance ceded
57 51 108 30 
Net other expenses
$82 $63 $278 $53 
Information regarding the significant effects of affiliated reinsurance on the interim condensed consolidated balance sheets was as follows at:
June 30, 2026December 31, 2025
Assumed CededAssumedCeded
(In millions)
Assets
Premiums, reinsurance and other
receivables (1)
$140 $10,908 $146 $11,017 
DAC and VOBA
113 (145)122 (149)
Total assets
$253 $10,763 $268 $10,868 
Liabilities
FPBs
$1,856 $— $1,941 $— 
PABs
8,145 — 8,441 — 
Other policy-related balances65 (59)69 (55)
Other liabilities798 9,291 934 9,582 
Total liabilities
$10,864 $9,232 $11,385 $9,527 
__________________
(1)Includes affiliated ceded PABs and FPBs.